Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women

DSpace/Manakin Repository

Show simple item record Grant, R. M. Liegler, T. Defechereux, P. Kashuba, A. D. Taylor, D. Abdel-Mohsen, M. Deese, J. Fransen, K. De Baetselier, I. Crucitti, T. Bentley, G. Agingu, W. Ahmed, K. Van Damme, L. 2015-08-07T09:26:56Z 2015-08-07T09:26:56Z 2015
dc.identifier.issn 0269-9370
dc.identifier.other ITG-C8A
dc.identifier.other ITG-C9B
dc.identifier.other ITG-C10A
dc.identifier.other DCS
dc.identifier.other U-ARLAB
dc.identifier.other JIF
dc.identifier.other DOI
dc.identifier.other Abstract
dc.identifier.other UPD58
dc.description.abstract BACKGROUND:: Pre-exposure prophylaxis (PrEP) with daily oral emtricitabine (FTC)/tenofovir disoproxil fumarate may select for drug resistance if there is low adherence. METHODS:: Plasma viral HIV-1 RNA level, CD4 T-cell counts, and drug resistance were evaluated among seroconverting women in the FEM-PrEP trial ( NCT00625404) using standard clinical tests, allele-specific PCR (ASPCR), and by deep sequencing. Tenofovir, FTC, and their intracellular metabolites were measured in plasma and cells. RESULTS:: There was no difference in plasma HIV-1 RNA level or CD4 cell count among seroconverters in the active arm versus those receiving placebo. Tenofovir resistance was not observed. FTC resistance was detected using clinical assays in five seroconverters (four in the active arm and one in the placebo arm); two in the active arm occurred among women having moderate concentrations of PrEP drugs in the blood. The first evidence of infection occurred at the first postenrollment visit in three of the four with FTC resistance, although none had detectable viral nucleic acids at enrollment. FTC-resistant minor variants were detected in an additional four seroconverters (one in the active arm and three in the placebo arm). CONCLUSIONS:: Drug resistance detected during ineffective PrEP use had characteristics suggesting transmitted infection or incubating infection prior to starting PrEP. en_US
dc.language English en_US
dc.subject Viral diseases en_US
dc.subject HIV-1 en_US
dc.subject AIDS en_US
dc.subject Women en_US
dc.subject Drug resistance en_US
dc.subject Pre-exposure en_US
dc.subject Prophylaxis en_US
dc.subject Emtricitabine en_US
dc.subject Tenofovir en_US
dc.subject Disoproxil en_US
dc.subject Fumarate en_US
dc.subject Compliance en_US
dc.subject RNA stability en_US
dc.subject T-cells en_US
dc.subject Disease transmission en_US
dc.subject Incubation en_US
dc.title Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women en_US
dc.type Article en_US
dc.citation.issue 3 en_US
dc.citation.jtitle AIDS en_US
dc.citation.volume 29 en_US
dc.citation.pages 331-337 en_US
dc.citation.jabbreviation AIDS en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record